Keyword: Icahn School of Medicine at Mount Sinai
A new study out of the Mount Sinai Icahn School of Medicine identifies the gene STMN2 as a key regulator of Parkinson’s disease.
Human-generated antibodies have provided new clues that could boost the development of a broadly protective antiviral drug and universal flu vaccine.
After one year, 14 out of 16 treated lesions tested negative for signs of cancer, according to procedure developer Nanospectra Biosciences.
Transplanting T-cells to immunotherapies could lead to better results in non-Hodgkin lymphoma, Mount Sinai scientists have found.
LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.
Mount Sinai researchers showed that in male mouse models of heart attack, Cdx2 placental cells regenerated damaged tissue.
Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.
Injecting a vaccine into tumor sites produced remissions in mice and some lymphoma patients in a study at Mount Sinai.
Researchers at Mount Sinai and IBM found a link between responses to some cancer treatments and mitochondria, the energy centers in cells.
Scientists from CUNY and the Icahn School of Medicine have identified a possible mechanism of action for Biogen's MS drug Tecfidera.